American Heart Journal
Volume 153, Issue 1 , Pages 98-104 , January 2007

Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure

  • Uri Elkayam, MD

      Affiliations

    • University of Southern California, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Uri Elkayam, MD, Heart Failure Program, USC School of Medicine, 2025 Zonal Ave, GH 7440, Los Angeles, CA 90033.
    • ,
  • Gudaye Tasissa, PhD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Cynthia Binanay, RN, BSN

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Lynne W. Stevenson, MD

      Affiliations

    • Brigham and Women's Hospital, Boston, MA
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, IL
    • ,
  • J. Wayne Warnica, MD

      Affiliations

    • University of Calgary, Calgary, Alberta, Canada
    • ,
  • James B. Young, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Barry K. Rayburn, MD

      Affiliations

    • University of Alabama at Birmingham, Birmingham, AL
    • ,
  • Joseph G. Rogers, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Teresa DeMarco, MD

      Affiliations

    • University of California at San Francisco Medical Center, San Francisco, CA
    • ,
  • Carl V. Leier, MD

      Affiliations

    • The Ohio State University, College of Medicine and Public Health, Columbus, OH

Received 31 May 2006 ,Accepted 20 September 2006.

  • Image Result

    Kaplan-Meier survival curve for all-cause mortality by intravenous vasoactive medication use.

    Kaplan-Meier survival curve for all-cause mortality by intravenous vasoactive medication use.

  • Image Result

    Kaplan-Meier survival curve for freedom from death or rehospitalization by intravenous vasoactive medication use.

    Kaplan-Meier survival curve for freedom from death or rehospitalization by intravenous vasoactive medication use.

 This study was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

PII: S0002-8703(06)00826-X

doi: 10.1016/j.ahj.2006.09.005

American Heart Journal
Volume 153, Issue 1 , Pages 98-104 , January 2007

Article Tools

* Image Usage & Resolution